Replies to post #3053 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Shionogi said the challenge study for their polymerase inhibitor should wrap up in Q4. I do think this is the most significant competitor even though PFE's fusion inhibitor is more advanced bc of the poor track record for prior fusion inhibitors.
Nice to see they completed enrollment of the peds study - that is the more significant event